R21/Matrix-M: WHO recommends Malaria vaccine made by Oxford and Serum Institute of India
vaccines." Adar Poonawalla, CEO of the Serum Institute of India, said “For far too long, malaria has threatened the lives of billions of people across the globe, disproportionately affecting the most vulnerable amongst us. This is why the WHO recommendation and approval of the R21/Matrix-M vaccine marks a huge milestone on our journey to combat this life-threatening disease, showing what exactly can be achieved when the public and private sector, scientists and researchers, all work together towards a shared goal." The vaccine was developed by the Jenner Institute at Oxford University and Serum Institute of India with support from the European and Developing Countries Clinical Trials Partnership (‘EDCTP’), the Wellcome Trust, and the European Investment Bank (‘EIB’).
R21/Matrix-M malaria vaccine will compete against the RTS,S shot by GSK Plc, which was recommended by the United Nations agency in 2021 and sold under the brand Mosquirix. Malaria kills over 600,000 each year globally, most of them children in Africa.
Read more on livemint.com
